Clinical Trial Update: A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating DE-127 ophthalmic solution for safety and efficacy in mild to moderate myopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• DE-127 ophthalmic solution (DE-127 ophthalmic solution)

Snippet

Sponsor: Santen Pharmaceutical Co., Ltd. | Conditions: Myopia | Phase 2 | Status: COMPLETED